•  home page
  •  location & contact
  • Español
entrechem entrechem
  • about us
    • founders
    • key personnel
    • funding
    • strategy
  • pipeline
    • pipeline chart
    • EC-8042
    • EC-70124
  • technology
    • natural products
    • synthetic biology
    • biocatalysis
      • DA · enantiomerically pure chiral diamines
      • AA · enantiomerically pure chiral amino alcohols
      • IA · enantiomerically pure chiral amino indanes
  • collaborations
    • scientific collaborators
    • collaborative projects
  • publications
    • EC-8042
    • EC-70124
    • biocatalysis
    • synthetic biology
  • news
entrechem entrechem
  • about us
    • founders
    • key personnel
    • funding
    • strategy
  • pipeline
    • pipeline chart
    • EC-8042
    • EC-70124
  • technology
    • natural products
    • synthetic biology
    • biocatalysis
      • DA · enantiomerically pure chiral diamines
      • AA · enantiomerically pure chiral amino alcohols
      • IA · enantiomerically pure chiral amino indanes
  • collaborations
    • scientific collaborators
    • collaborative projects
  • publications
    • EC-8042
    • EC-70124
    • biocatalysis
    • synthetic biology
  • news
Mar 26

EntreChem’s kinase inhibitor shows potential for treatment of head and neck cancer

  • 26 March, 2012
  • Research
  • The PI3K/Akt/PTEN molecular pathway is frequently mutated in this type of tumor, where activation of the Akt kinase is a poor prognosis factor, according to researchers at CIEMAT.
  • EC-70124, a kinase inhibitor under development at EntreChem SL, has shown efficacy in a murine model of Head & Neck cancer that expresses a permanently active form of the Akt1 kinase together with loss of Trp53.

The results of a public-private collaborative research from EntreChem SL (Oviedo) and CIEMAT (Research Center for Energy, Environment and Technology, in Madrid) focused on searching for a new strategy for Head and Neck Squamous Cell Carcinoma, one of the 10 most common cancers worldwide, has been presented in a poster in the Cold Spring Harbor Symposium “PTEN Pathways and Targets” held on March 13th-16th in New York.

The research, directed by Dr. Jesús Paramio, Head of the Molecular Oncology Unit at CIEMAT, makes use of a HNSCC mouse model, myrAkt;Trp53Epi, which expresses a permanently active form of the Akt1 kinase together with loss of Trp53 expression in the basal layer of stratified epithelia. Oral tumors in these animals have a high incidence and they are phenotipycally similar to human HNSCC.EC-70124 reduces oral keratinocyte cell viab

ility in a dose-dependent manner, and it specifically affects myrAkt;Trp53Epi protumoral cells, both in vitro and in vivo. EC-70124 regulates PI3K/Akt/PTEN pathway in myrAkt;Trp53Epi oral keratinocytes. The molecule EC-70124, a selective kinase inhibitor, reduces myrAkt;Trp53Epi tumor growth in immunodeficient mice administered intraperitoneally at doses well below toxic levels in mice.

The inhibitor EC-70124, is currently undergoing preclinical development by EntreChem SL (therefore not yet available for human assays). EC-70124 is a hybrid natural product obtained from genetically modified bacteria by combinatorial biosynthesis.

EntreChem SL is a spin off company created from research developed in the University of Oviedo, and its shareholders include, aside from the original co-founders, local industry companies such as Industrial Química del Nalón, Alvargonzález SA and Alimerka. Private financing is complemented by regional, national and european public programs like NEOTEC program (MICINN), Genome Spain Foundation, FICYT, IDEPA, SRP and the Seventh Framework Programme from the European Union.

More information:
http://meetings.cshl.edu/meetings/abstracts/pten2012_absstat.html
Dr. Jesús M. Paramio: jesusm.paramio@ciemat.es, +34 914 962 517
Dr. Francisco Morís Varas: fmv@entrechem.com, +34 985 259 021

and also:
CIEMAT: www.ciemat.es (basic research, epithelial biomedicine)
EntreChem SL: www.entrechem.com

latest news

  • AI-Therapeutics acquires the preclinical drugs EC-8042 and EC-70124 from EntreChem SL
  • EC-8042 targets SWI/SNF complex vulnerabilities and induces epigenetic reprogramming and permanent cures in rhabdoid tumor
  • EntreChem participates in the ERA-Co-Biotech project «MISSION»

categories

  • Agreements
  • Financing
  • Projects
  • Publications
  • Research
  • Other

archive

EntreChem, S.L.

Vivero Ciencias de la Salud,
c/ Colegio Santo Domingo de Guzmán s/n,
33011 Oviedo, Spain

info@entrechem.com

pipeline  /  chart
· EC-8042
· EC-70124

scientific collaborators
collaborative projects

  • about us
  • technology
  • publications
  • news
Copyright © 2023 EntreChem, S.L. All rights reserved.
  • privacy policy
  • usage policy
  • cookies policy

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

Privacy Overview
entrechem

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!

Cookie Policy

You can consult our cookies policy for more information.